Compromised longevity due to *Mycobacterium abscessus* pulmonary disease in lungs scarred by tuberculosis

Urvashi B. Singh1,*, Rojaleen Das1, Prajowl Shrestha2, Kiran Bala1, Pooja Pandey1, Santosh Kumar Verma1, Hitender Gautam1, Elizabeth Story-Roller3, Gyanu Lamichhane3 and Randeep Guleria2,*

CASE

A 56-year-old non-smoking male, retired army personnel, presented to the pulmonary outpatient clinic with symptoms of fever, productive cough and weight loss in March 2015 at AIIMS, New Delhi. He had initially presented with symptoms of fever, expectoration, weight loss and loss of appetite in 2012. He was given empirical anti-tubercular treatment for a clinical diagnosis of tuberculosis (TB) for 13 consecutive months with no improvement in 2013. The patient had been treated for pleural effusion in 1997, and declared cured. In March 2015 the patient reported to our institute. Examination revealed bilateral bronchial breath sounds in the upper and lower chest regions. His sputum samples were acid-fast bacilli (AFB)-positive and indicated suspected relapse of TB. Treatment was initiated with six drugs, including rifampicin, isoniazid, ethambutol, clarithromycin, levofloxacin and linezolid with a supplement of vitamin B6. However, his symptoms worsened (Fig. 1).

INVESTIGATIONS

A complete blood count showed elevated lymphocyte and monocyte counts of 14.9 * 10^3 µl⁻¹ and 8.9 * 10^3 µl⁻¹, respectively, as well as an elevated erythrocyte sedimentation rate (ESR) of 40 mm after 1 h. Blood chemistry findings were normal. The patient was non-reactive for HIV 1 and 2 as well as hepatitis B and C. The workup for other bacteria and fungi was negative. A chest X-ray showed pleural thickening with hydropneumothorax and bilateral fibrous parenchymal lesions (Fig. 2). Sputum microscopy was positive with a Revised National Tuberculosis Control Program grading of (1+). A Gene Xpert assay was performed on the sample and was found to be negative. Culture on Lowenstein–Jensen (LJ) medium and Mycobacteria Growth Indicator Tube (MGIT 960) grew short, slender and curved AFB within 5 and 3 days, respectively, indicating a rapidly growing organism. An MGIT TBc identification test (Becton Dickinson) was negative and other bacteria were ruled out by culture. Subculture on LJ medium showed buff and pasty colonies within 5 days, indicating a rapid grower.

Abstract

Structural lung diseases or scarring related to prior infections such as tuberculosis (TB) are risk factors for the development of invasive nontuberculous mycobacterial (NTM) pulmonary infections, such as *Mycobacterium abscessus*. *M. abscessus* is intrinsically resistant to many antibiotics and in vitro susceptibility correlates poorly with clinical response, especially in pulmonary disease. Treatment is often difficult due to the lack of effective antibiotic regimens. We present a case of a 56-year-old male previously treated for TB, with presumed exacerbation, who was diagnosed after much delay with pulmonary *M. abscessus* disease and subsequently failed initial treatment with an empirical antibiotic regimen. When placed on a synergistic combination regimen that included amikacin, linezolid, clarithromycin, ethambutol and faropenem, the patient showed a favourable response and was culture-negative for over 12 months when the treatment was stopped as per American Thoracic Society (ATS) recommendations. Unfortunately, he developed recurrent symptoms and died 9 months after stopping treatment, following an acute exacerbation of fever and respiratory failure.
The isolate was negative for a niacin accumulation test, a heat-stable catalase test and a nitrate reductase test, while it was NaCl-tolerant and grew on MacConkey’s medium. Hence, it was identified as *Mycobacterium abscessus*. A second sputum sample was also identified as *M. abscessus*. Hence, *M. abscessus* was clearly the pathogen in this case scenario (ATS, American Thoracic Society guidelines) [1]. The isolate was subsequently sequenced for the 16S ribosomal gene and confirmed as *M. abscessus*, and the sequence was submitted to GenBank and assigned accession no. MF287216.

*M. abscessus* is intrinsically resistant to many antibiotics and in vitro susceptibility correlates poorly with clinical response, especially in pulmonary disease [2–4]. Drug susceptibility testing on the isolate demonstrated resistance to amikacin, imipenem, moxifloxacin and linezolid based on established minimum inhibitory concentration (MIC) breakpoints [5]. Of note, the isolate was susceptible to clarithromycin. Several studies have demonstrated synergy between antibiotics against *M. abscessus in vitro*, which has the potential to decrease the MIC of both drugs and overcome antibiotic resistance. Synergy between linezolid and clarithromycin [6, 7] and linezolid and amikacin [8], as well as several carbapenems and rifampicin [9], have been described. Additionally, although the MIC of ethambutol was not specifically tested and many *M. abscessus* isolates tend to harbour inherent resistance to ethambutol [10], cases of ethambutol inclusion in treatment regimens against *M. abscessus* have been documented [11].

Given the extensive resistance profile of this isolate, the potential for synergy of the above-listed drugs in combination with faropenem was tested (Table 1). The MIC results from these tests, in addition to the synergy studies cited above, were used to develop an antibacterial treatment regimen for the patient. Adjunctive surgical resection unfortunately could not

---

**Fig. 1.** Time line of events. H, isoniazid; R, rifampicin; Z, pyrazinamide; E, ethambutol; Lvx, levofloxacin; Clari, clarithromycin; Faro, faropenem; DST, drug susceptibility testing.

---

**Fig. 2.** (a) Chest X-ray PA view (November 2015) shows pleural thickening and calcification of right lung with multiple scattered lung nodules and cystic lucencies ion the right side of the lung. Chest X-ray (March 2017) shows pleural thickening and calcification of right lung with multiple scattered lung nodules and cystic lucencies ion the right side of the lung. There is resolution of left middle zone lung infiltrates. Compensatory hyperinflation of left lung is noted. (b) Chest computed tomography (CT) (December 2015) showed right upper lobe thick-walled cavity with irregular internal wall. There are areas of centrilobular nodules surrounding the cavity and left upper lobe, suggesting an active infective process. However, a chest CT in March 2017 showed that the centrilobular nodules in the left lower lobe had decreased as compared to those in the previous one.
be considered in this case due to the involvement of more than half of the right lung.

Given the reported disconnect between the in vitro susceptibility of M. abscessus and clinical response [4], the decision was made to treat the patient with linezolid (300 mg daily), clarithromycin (500 mg twice daily), ethambutol (1 g daily) and faropenem (200 mg three times daily) for 1 year, with the addition of intravenous amikacin for the initial 2-month induction phase. After 3 weeks of treatment, the patient reported improvement of symptoms, including weight gain and decreased cough. Follow-up sputum cultures converted to negative within 1 month of treatment and the patient continued on this regimen as an outpatient without any adverse effects. His condition continued to improve gradually and he became persistently culture-negative for 12 months after starting treatment, at which time antibiotics were stopped as per American Thoracic Society (ATS) recommendations [1]. The patient remained asymptomatic for the next 9 months, but subsequently developed recurrence of respiratory symptoms. He unfortunately succumbed to an acute exacerbation of fever and respiratory failure before he could report to our institute.

**DISCUSSION**

Prior pulmonary TB and bronchiectasis are predisposing conditions for M. abscessus pulmonary infection and most patients with lung disease due to M. abscessus are more than 60 years of age [1]. The disease usually presents with symptoms that are similar to those of other respiratory pathogens, including cough and easy fatigability, and it is difficult to differentiate from TB by radiography. M. abscessus is intrinsically resistant to several classes of antibiotics and is known to produce poor clinical response even to agents showing in vitro susceptibility. This is especially true in the setting of pulmonary disease [1]. Current guidelines recommend prolonged multidrug therapy to minimize the chances of relapse [1, 12]. Chronic pulmonary disease due to nontuberculous mycobacteria (NTM) is difficult to treat and rarely cured [13].

According to the ATS guidelines, there are no regimens of proven efficacy for treating pulmonary disease caused by M. abscessus. The ATS recommends a clarithromycin-based multidrug regimen, along with surgical resection of localized disease. However, not all subspecies of M. abscessus are susceptible to clarithromycin. Recently, inducible resistance to clarithromycin has been described in M. abscessus isolates on extended incubation in vitro and the *erm* gene confers naturally inducible resistance in vivo. The production of Erm (41) methyltransferase predicts clinical failure for clarithromycin [14]. This further complicates the development of adequate treatment regimens.

As stated above, several studies have demonstrated the synergistic activity of various classes of antibiotics against M. abscessus. Emerging evidence suggests that the carbapenem and penem classes of β-lactams are potent against M. abscessus [15, 16]. Additionally, there is a case report of successful treatment of M. abscessus pulmonary disease with a combination of faropenem and clarithromycin [17]. Hence, faropenem, a new, orally bioavailable penem, which

---

**Table 1.** Synergistic effect on MIC from the addition of faropenem to rifampicin, amikacin, moxifloxacin and linezolid. Clinical and Laboratory Standards Institute drug susceptibility testing breakpoints for M. abscessus: rifampicin (not established), imipenem (MIC≥16 µg ml⁻¹), amikacin (MIC≥64 µg ml⁻¹), linezolid (MIC≥32 µg ml⁻¹) and moxifloxacin (MIC≥4 µg ml⁻¹). Faropenem tested at 0.625 µg ml⁻¹ in synergy studies

| Drug name                        | Drug concentrations |
|----------------------------------|---------------------|
| 10 µg ml⁻¹                        | 5 µg ml⁻¹           |
| Faropenem only                    | Resistant           |
|                                  | 2.5 µg ml⁻¹         |
|                                  | 1.25 µg ml⁻¹        |
|                                  | 0.625 µg ml⁻¹       |
| 1.0 µg ml⁻¹                       | 0.5 µg ml⁻¹         |
| Rifampicin only                   | Resistant           |
|                                  | 0.25 µg ml⁻¹        |
|                                  | 0.12 µg ml⁻¹        |
|                                  | 0.063 µg ml⁻¹       |
| 64 µg ml⁻¹                        | 32 µg ml⁻¹          |
| Rifampicin and faropenem          | Susceptible         |
|                                  | 16 µg ml⁻¹          |
|                                  | 8 µg ml⁻¹           |
|                                  | 4 µg ml⁻¹           |
| Amikacin only                     | Susceptible         |
|                                  | 128 µg ml⁻¹         |
|                                  | 64 µg ml⁻¹          |
|                                  | 32 µg ml⁻¹          |
|                                  | 16 µg ml⁻¹          |
|                                  | 8 µg ml⁻¹           |
| Amikacin and faropenem            | Susceptible         |
|                                  | 4 µg ml⁻¹           |
|                                  | 2 µg ml⁻¹           |
|                                  | 1 µg ml⁻¹           |
|                                  | 0.5 µg ml⁻¹         |
|                                  | 0.25 µg ml⁻¹        |
| Linezolid only                    | Susceptible         |
|                                  | 4 µg ml⁻¹           |
|                                  | 2 µg ml⁻¹           |
|                                  | 1 µg ml⁻¹           |
|                                  | 0.5 µg ml⁻¹         |
|                                  | 0.25 µg ml⁻¹        |
| Linezolid and faropenem           | Susceptible         |
| Moxifloxacin only                 | Susceptible         |
|                                  | Susceptible         |
|                                  | Susceptible         |
|                                  | Susceptible         |
| Moxifloxacin and faropenem        | Susceptible         |

µg ml⁻¹, microgram per millilitre.
exhibits a broad spectrum of activity against Gram-negative, Gram-positive and anaerobic bacteria [18], as well as synergistic efficacy against M. abscessus [9], was included in the regimen.

In the present case, in vitro synergy was demonstrated against the isolate, as the addition of faropenem reduced the MIC of rifampicin by 16-fold, that of amikacin by 4-fold, and that of moxifloxacin by 2-fold, although no change was seen in the MIC of linezolid with the addition of faropenem (Table 1). Based on these studies, a multidrug treatment regimen was designed that included 2 months of intravenous (IV) amikacin during the initial induction phase of treatment, combined with oral linezolid, clarithromycin, ethambutol and faropenem, which were continued for 1 year, although the isolate was resistant to amikacin, linezolid and faropenem individually in vitro. The patient showed rapid clinical and microbiological improvement within a month of treatment initiation. Subsequently, the patient continued to have negative sputum cultures throughout the duration of treatment, even after the discontinuation of IV amikacin.

This novel oral regimen of linezolid, clarithromycin, ethambutol and faropenem contributed to successful treatment of this patient’s infection, as evidenced by the clinical resolution of symptoms and maintenance of culture negativity for 12 months. It is interesting to note that this patient had initially been considered to have a relapsed or recurrent TB infection upon presentation to our institute and was hence treated with rifampicin, isoniazid, ethambutol, clarithromycin, levofloxacin and linezolid; however, his symptoms persisted. Therefore, it may be reasonable to assume that the addition of faropenem to his M. abscessus treatment regimen significantly increased the efficacy of the regimen, as the prior empirical regimen containing the other three oral antibiotics (linezolid, clarithromycin and ethambutol) had not improved his symptoms. The use of IV amikacin during the induction phase of treatment likely contributed to his rapid sputum culture conversion, but also exhibited synergy with faropenem, potentially making it more effective.

Subsequently, the patient remained asymptomatic for few months, having assumed that he was cured. Unfortunately, 9 months after stopping therapy the patient developed recurrence of symptoms, which ultimately led to respiratory failure and death, presumably due to relapse of infection. Ideally, post-mortem analysis would have been helpful to confirm relapsed M. abscessus infection as the cause of death, but this was not feasible (Fig. S1, available in the online version of this article).

This case emphasizes how difficult it is to achieve an effective cure in the setting of M. abscessus pulmonary disease, which was also noted in a recent systematic review that reported relapse-free sputum culture conversion rates of as low as 25% despite prolonged multidrug therapy [19]. This case also highlights the importance of close medical follow-up in these patients even after the completion of treatment, given the high rate of relapse.

### Conclusion

Early diagnosis of M. abscessus pulmonary disease is imperative for the initiation of appropriate treatment and the prevention of further damage to infected tissues. This patient likely developed M. abscessus lung disease as a result of his prior TB infection, which caused lung scarring and bronchiectasis, and was further exacerbated by delayed diagnosis of a nontuberculous mycobacterial infection. In vitro susceptibility to antimicrobial agents does not always correlate with clinical response in pulmonary disease due to M. abscessus, which may hinder the development of appropriate treatment regimens. Several studies have reported synergy among various classes of antibiotics against M. abscessus, which have the potential to overcome drug resistance when used in combination. Although this patient ultimately succumbed to a presumed relapse of infection 9 months after the cessation of antibiotics, his novel multidrug regimen resulted in persistent sputum culture negativity during the 12 months of treatment, which indicates treatment success per the ATS guidelines. This case describes the successful use of a novel synergistic antibiotic regimen against a highly drug-resistant strain of M. abscessus. It also emphasizes the importance of close medical follow-up after the cessation of treatment and early intervention in the setting of relapsed disease.

### Funding information

The authors received no specific grant from any funding agency.

### Acknowledgements

We acknowledge the staff of the tuberculosis laboratory.

### Author contributions

Dr Urvashi B. Singh designed the strategy of diagnosis and identification of isolate, antibiotic susceptibility testing including synergistically acting drugs, suggestions with treatment regimen and drafting of this case report. Dr Rosaleen helped with identification of isolate in the laboratory. Dr Prajwol Shrestha was involved in patient’s work up along with management and follow up. Dr Kiran Bala was involved with acquisition, analysis and interpretation of data for the work. Mr Santosh Kumar Verma performed the polymerase chain reaction and isolation of DNA. Ms Pooja Pandey completed 16S rRNA sequencing and submitted to Gene-bank. Dr Hitender Gautam was involved with diagnostic work up of patient along with antibiotic susceptibility of isolate. Dr Gyanu Lachichane and Dr Elizabeth Story-Roller were involved in conceptualizing the idea of adding β-lactam to the multidrug treatment regimen. Dr Randeep Guleria supervised the management, designing the treatment regimen and follow up of patient. Both Dr Urvashi Singh and Dr Randeep Guleria have revised the manuscript critically for important intellectual content.

### Conflicts of interest

The authors declare that there are no conflicts of interest.

### Ethical statement

The authors have no ethical conflicts to disclose. Consent to publish the findings was obtained from the patient’s family.

### References

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367–416.

2. Daley CL, Griffith DE. Pulmonary disease caused by rapidly growing mycobacteria. Clin Chest Med 2002;23:623–632.
3. Greendyke R, Byrd TF. Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. Antimicrob Agents Chemother 2008;52:2019–2026.

4. Maurer FP, Bruderer VL, Ritter C, Castelberg C, Bloemberg GV et al. Lack of antimicrobial bactericidal activity in Mycobacterium abscessus. Antimicrob Agents Chemother 2014;58:3828–3836.

5. Standards NCCLS. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; Approved Standard. Wayne, PA: NCCLS; 2003.

6. Cremades R, Santos A, Rodriguez JC, Garcia-Pachón E, Ruiz M et al. Mycobacterium abscessus from respiratory isolates: activities of drug combinations. J Infect Chemother 2012;67:810–818.

7. Oh CT, Moon C, Park OK, Kwon SH, Jang J. Novel drug combination for Mycobacterium abscessus disease therapy identified in a Drosophila infection model. J Antimicrob Chemother 2014;69:1599–1607.

8. Zhang Z, Lu J, Song Y, Pang Y. In vitro activity between linezolid and other antimicrobial agents against Mycobacterium abscessus complex. Diagn Microbiol Infect Dis 2018;90:31–34.

9. Kaushik A, Makkar N, Pandey P, Parrish N, Singh U et al. Carbapenems and rifampin exhibit synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. Antimicrob Agents Chemother 2015;59:6561–6567.

10. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: a new antibiotic nightmare. J Antimicrob Chemother 2012;67:810–818.

11. Novosad SA, Beekmann SE, Polgreen PM, Mackey K, Winthrop KL et al. Treatment of Mycobacterium abscessus infection. Emerg Infect Dis 2016;22:511–514.

12. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL et al. US cystic fibrosis foundation and European cystic fibrosis society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016;71:1–22.

13. Jarand J, Levin A, Zhang L, Huitl G, Mitchell JD et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011;52:565–571.

14. Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009;53:1367–1376.

15. Kaushik A, Gupta C, Fisher S, Story-Roller E, Galanis C et al. Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus. Future Microbiol 2017;12:473–480.

16. Story-Roller E, Maggioncalda EC, Cohen KA, Lamichhane G. Mycobacterium abscessus and β-lactams: emerging insights and potential opportunities. Front Microbiol 2018;9:2273.

17. Tanaka E, Kimoto T, Tsuyuguchi K, Suzuki K, Amitani R. Successful treatment with faropenem and clarithromycin of pulmonary Mycobacterium abscessus infection. J Infect Chemother 2002;8:252–255.

18. Woodcock JM, Andrews JM, Brenwald NP, Ashby JP, Wise R. The in-vitro activity of faropenem, a novel oral penem. J Antimicrob Chemother 1997;39:35–43.

19. Diel R, Ringshausen F, Richter E, Welker L, Schmitz J et al. Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis. Chest 2017;152:120–142.